Bevacizumab plus Low-Dose Metronomic Oral Cyclophosphamide in Heavily Pretreated Patients with Recurrent Ovarian Cancer - Concepedia

Concepedia

Publication | Open Access

Bevacizumab plus Low-Dose Metronomic Oral Cyclophosphamide in Heavily Pretreated Patients with Recurrent Ovarian Cancer

DOI Full Paper Access

53

Citations

14

References

2010

Year

Alfonso Sánchez‐Muñoz, César Mendiola, Elísabeth Pérez-Ruiz, César Augusto Rodríguez‐Sánchez, J.M. Jurado, Lorenzo Alonso-Carrión, Ismael Ghanem, Guillermo de Velasco, Cristina Quero-Blanco, Emilio Alba

Abstract

The combination of bevacizumab and metronomic cyclophosphamide was active and well-tolerated in heavily pretreated patients with recurrent ovarian cancer.

References

	Year	Citations

Page 1